Press releases

16 Dec 2024

Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program

29 Nov 2024

UCB Focuses on New Launch and Completes Divestment of Mature Product Business in China

27 Nov 2024

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

20 Nov 2024

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa

19 Nov 2024

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

18 Nov 2024

Transparency notification BlackRock, Inc.

Press releases

Press releases

Search Press releases

Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program

UCB Focuses on New Launch and Completes Divestment of Mature Product Business in China

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Transparency notification BlackRock, Inc.

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program

UCB Focuses on New Launch and Completes Divestment of Mature Product Business in China

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Transparency notification BlackRock, Inc.

Choose a Country